Circulogene

Circulogene provides valuable information to physicians about cell free DNA tumor resistance and recurrence, metastasis, and treatment protocols and progress. 
Applying its proprietary laboratory developed test for cfDNA liquid biopsies, Circulogene has developed the only droplet-volume, next-generation sequencing (NGS) method to provide full genomic load analysis, enabling more accurate data to help clinicians and their patients.

With a simple finger stick, Circulogene’s patented technology utilizes NGS to monitor known tumor mutations (approximately 3,000) in 50 established cancer-associated genes and further provides information on current FDA-approved treatment options.

• CLIA-ready

• Clinically validated assays

• Unprecedented high recovery of cell-free DNA from droplet volumes of blood translates into high sensitivity

• Open platforms, Ion Torrent Proton for both mutation monitoring and profiling

• Integrated workflow for consistent and reliable longitudinal studies